Evidence map›Paper›PMID 35390787›Full record

ArticleCerebrovascular diseases (Basel, Switzerland)2022

A Chilean Experience of Telestroke in a COVID-19 Pandemic Year.

Carlos Delfino, Enrico Mazzon, Gabriel Cavada, Paula Muñoz Venturelli, Alejandro M Brunser, Felipe Jurado Díaz, Lorena Lara Cisternas, Diego Rocha Jiménez, Mirya Arévalo Valdivia, Diego Rojas Torres and 1 more

Open access · greenAbstract readNews
In one paragraph

Article in Cerebrovascular diseases (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Carlos DelfinoCentro de Estudios Clínicos, Instituto de Ciencias e Innovación en Medicina (ICIM), Facultad de Medicina, Clínica Alemana Universidad del Desarrollo, Santiago, Chile, cdelfino@udd.cl.
Enrico MazzonCentro de Estudios Clínicos, Instituto de Ciencias e Innovación en Medicina (ICIM), Facultad de Medicina, Clínica Alemana Universidad del Desarrollo, Santiago, Chile.
Gabriel CavadaResearch and Clinical Trials Unit, Department of Academic Development and Research, Clínica Alemana de Santiago, Santiago, Chile.
Paula Muñoz VenturelliCentro de Estudios Clínicos, Instituto de Ciencias e Innovación en Medicina (ICIM), Facultad de Medicina, Clínica Alemana Universidad del Desarrollo, Santiago, Chile.
Alejandro M BrunserUnidad de TeleACV, Servicio de Salud Metropolitano Sur, Santiago, Chile.
Felipe Jurado DíazUnidad de TeleACV, Servicio de Salud Metropolitano Sur, Santiago, Chile.
Lorena Lara CisternasUnidad de TeleACV, Servicio de Salud Metropolitano Sur, Santiago, Chile.
Diego Rocha JiménezUnidad de TeleACV, Servicio de Salud Metropolitano Sur, Santiago, Chile.
Mirya Arévalo ValdiviaUnidad de TeleACV, Servicio de Salud Metropolitano Sur, Santiago, Chile.
Diego Rojas TorresUnidad de TeleACV, Servicio de Salud Metropolitano Sur, Santiago, Chile.
Eloy MansillaCentro de Estudios Clínicos, Instituto de Ciencias e Innovación en Medicina (ICIM), Facultad de Medicina, Clínica Alemana Universidad del Desarrollo, Santiago, Chile.
Universidad del Desarrollo · CLClínica Alemana · CLUniversity of Chile · CL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposeTelemedicine for stroke patients' care (telestroke [TS]) has grown notably in recent decades and may offer advantages during health crisis. Hospital admissions related to stroke have decreased globally during the COVID-19 pandemic, but scarce information is available regarding the effect of COVID-19 in TS. Using a population-based TS registry, we investigated the impact of the first year of the COVID-19 pandemic throughout our TS network in Santiago, Chile.

methodsStroke codes evaluated after the onset of COVID-19 restrictions in Chile (defined as March 15, 2020) were compared with those evaluated in 2019. We analyzed differences between number of stroke codes, thrombolysis rate, stroke severity, and time from the stroke onset to hospital admission.

resultsWe observed that the number of stroke codes and the number of patients undergoing reperfusion therapy did not change significantly (p = 0.669 and 0.415, respectively). No differences were found with respect to the median time from the stroke onset to admission (p = 0.581) or in National Institutes of Health Stroke Scale (NIHSS) scores (p = 0.055). The decision-making-to-needle time was significantly shorter in the COVID-19 period (median 5 min [IQR 3-8], p < 0.016), but no significant changes were found at the other times.

conclusionsThis study demonstrates the potential of adapting TS to extreme situations such as the COVID-19 pandemic, as well as the importance of establishing networks that facilitate patient access to quality treatments.

Indexed as

COVID-19StrokeTelemedicineChileHumansPandemicsThrombolytic TherapyCOVID-19Pandemic diseaseStrokeTelemedicineTelestrokeThrombolysis

Identifiers

PMID35390787
PMCPMC9148905
OpenAlexW4226083331

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.